Surgical scars treated with a molecule called alphaCT1 showed a long-term improvement in appearance when compared to control scars, according to multicenter, controlled Phase II clinical trials – a finding

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

Existing Users Log In